• No image available for this medication

    • PREPARATION H (Generic for HEMORRHOIDAL SUPPOSITORY)

    • QTY 24
    • 0.25-88.44
    • SUPP.RECT

PREPARATION H (Generic for HEMORRHOIDAL SUPPOSITORY) Lifestyle Interactions

  • Posaconazole 100mg, Oral tablet, gastro-resistant

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: Side effects from posaconazole may result if given with grapefruit juice. Theoretically, grapefruit juice can alter the elimination of posaconazole from the body, and can lead to increased side effects. Your prescriber may decide that taking these together is beneficial for you based on your health conditions. Discuss your drug regimen and health conditions with your health care provider.
    • Notes for Professionals: Posaconazole and grapefruit juice should be coadministered with caution due to a potential for altered posaconazole plasma concentrations. Both posaconazole and grapefruit juice are inhibitors of the drug efflux protein, P-glycoprotein, for which posaconazole is a substrate. This interaction may cause alterations in the plasma concentrations of posaconazole, ultimately resulting in an increased risk of adverse events.

  • Posaconazole 100mg, Oral tablet, gastro-resistant

    • Interaction: Marijuana
    • Severity: Moderate
    • Notes for Consumers: The effects of marijuana may be increased and side effects may get worse if it is combined with this medicine. Do not drive or operate machinery until you know how this combination will affect you. Contact your health care provider right away if you notice slurred speech, confusion, severe drowsiness, increased heart rate, or any other new or unusual side effects.
    • Notes for Professionals: The incidence of marijuana associated adverse effects may change following coadministration with posaconazole. Posaconazole is an inhibitor of CYP3A4, an isoenzyme partially responsible for the metabolism of marijuana's most psychoactive compound, delta-9-tetrahydrocannabinol (Delta-9-THC). When given concurrently with posaconazole, the amount of Delta-9-THC converted to the active metabolite 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) may be reduced. These changes in Delta-9-THC and 11-OH-THC plasma concentrations may result in an altered marijuana adverse event profile.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.